SEOUL, South Korea--(BUSINESS WIRE)--Dong-A ST (President/CEO Jae-Hun Jung, KRX: 170900) announced on October 11 that Imuldosaâ„¢ (ustekinumab-srlf/DMB-3115), a ...
Both etanercept and ustekinumab have been shown to be strikingly effective in patients with psoriasis. A phase III trial comparing these two biologic agents for the treatment of moderate-to-severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback